ArticleBMC cancer2023

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.

Francesca Corti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.